Related Experiment Videos
[Short-term ceftriaxone treatment of typhoid fever in children]
1Department of Pediatrics, Taiwan Provincial Tao-Yuan General Hospital, R.O.C.
Insights
Short-term intravenous Ceftriaxone effectively treated pediatric typhoid fever. This antibiotic demonstrated rapid response, no serious side effects, and a low failure rate in young patients.
Area of Science:
- Pediatric infectious diseases
- Pharmacology and therapeutics
Context:
- Typhoid fever remains a significant public health concern, particularly in children.
- Effective and safe antibiotic treatments are crucial for managing pediatric typhoid fever.
- Intravenous Ceftriaxone is a third-generation cephalosporin antibiotic used for various bacterial infections.
Purpose:
- To evaluate the efficacy and safety of short-term intravenous Ceftriaxone in treating children diagnosed with typhoid fever.
Summary:
- Ten children with typhoid fever received intravenous Ceftriaxone (50-100 mg/kg/day) for a minimum of five days.
- The mean defervescence period was 3.2 days.
- All patients completing the treatment were cured, with no reported adverse reactions, relapses, or chronic carriers.
Impact:
- Short-term intravenous Ceftriaxone offers a rapid, safe, and effective treatment option for pediatric typhoid fever.
- This regimen minimizes the risk of serious side effects and treatment failure in children.
- The findings support Ceftriaxone as a valuable therapeutic agent in pediatric infectious disease management.
Abstract:
Ten children, diagnosed as having typhoid fever, were enrolled in this study between April and September, 1989. Ceftriaxone was administered intravenously, in two dosages adding to 50-100 mg/kg/day over as short a period as five days. The mean period of defervescence was 3.2 days. No adverse reactions to the drug occurred; all those fulfilling the prescribed course were cured. To date, no relapse has been reported nor has any patient become a chronic carrier. Shortterm use of Ceftriaxone had the advantages of rapid response, abscence of serious side effects, and low failure rate in treating children with typhoid fever.